Diabetic foot infection occurs in patients with diabetes as they are prone to microorganism invasion and multiplication in the soft tissue or bone (anywhere below the malleoli) that leads to host inflammatory response that usually results to tissue destruction.
Staphylococci and streptococci are the most common causative organisms although most diabetic foot infections are polymicrobial.
Most infections usually start with a break in the protective cutaneous envelope of the skin that resulted from trauma or neuropathic ulceration.
Management of diabetic foot ulcer in patients with diabetes needs an interdisciplinary approach to address glycemic control, infection, offloading of high-pressure areas, lower extremity vascular status and local wound care.
A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).
As the dust settles from the SARS-CoV-2 pandemic, the lurking threat of antimicrobial resistance (AMR) once again rears its ugly head. Weighing in on this topic is Professor Dr Sasheela Sri La Sri Ponnampalavanar, Infectious Disease Professor, University Malaya Medical Centre (UMMC). Below is an excerpt from her bylined piece titled ‘Tackling the Next Global and Public Health Threat After COVID-19 – Antimicrobial Resistance (AMR).’
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.